<clinical_study>
  <!-- This xml conforms to an XML Schema at:
    https://clinicaltrials.gov/ct2/html/images/info/public.xsd -->
  <required_header>
    <download_date>ClinicalTrials.gov processed this data on July 28, 2020</download_date>
    <link_text>Link to the current ClinicalTrials.gov record.</link_text>
    <url>https://clinicaltrials.gov/show/NCT00282659</url>
  </required_header>
  <id_info>
    <org_study_id>WHIT001799HI</org_study_id>
    <nct_id>NCT00282659</nct_id>
  </id_info>
  <brief_title>The Use of Magnesium to Improve Blood Pressure, Cholesterol, and Glucose Control</brief_title>
  <official_title>The Use of Magnesium to Improve Hemodynamics, Cholesterol, and Glucose Control: A Substudy of AdMag</official_title>
  <sponsors>
    <lead_sponsor>
      <agency>Hartford Hospital</agency>
      <agency_class>Other</agency_class>
    </lead_sponsor>
  </sponsors>
  <source>Hartford Hospital</source>
  <brief_summary>
    <textblock>
      The purpose of this study is to determine if magnesium can improve blood pressure,
      cholesterol, and blood sugar control in patients with implantable cardioverter defibrillators
      (ICDs).
    </textblock>
  </brief_summary>
  <detailed_description>
    <textblock>
      Magnesium is the second most abundant intracellular cation and plays a vital role in many
      physiologic processes. It has been determined that patients with cardiovascular disease have
      intracellular magnesium (Mgi) deficiencies. Among the ICD registries in Europe and the United
      States 64% and 77% of patients also carry the diagnosis of CAD, respectively. Patients with
      CAD have risk factors that lead to the development and or propagation of atherosclerosis.
      Paramount among these risk factors are hypertension, dyslipidemia, and diabetes.

      Comparison: Magnesium compared to placebo in patients with ICDs to evaluate the effect they
      have on cholesterol, blood pressure, and blood glucose.
    </textblock>
  </detailed_description>
  <overall_status>Completed</overall_status>
  <start_date>January 2006</start_date>
  <completion_date type="Actual">June 2008</completion_date>
  <primary_completion_date type="Actual">June 2008</primary_completion_date>
  <phase>Phase 4</phase>
  <study_type>Interventional</study_type>
  <has_expanded_access>No</has_expanded_access>
  <study_design_info>
    <allocation>Randomized</allocation>
    <intervention_model>Parallel Assignment</intervention_model>
    <primary_purpose>Treatment</primary_purpose>
    <masking>Double</masking>
  </study_design_info>
  <primary_outcome>
    <measure>Blood pressure, cardiac output, systemic vascular resistance, thoracic fluid content, total cholesterol, low density lipoprotein, high density lipoprotein, triglycerides, and blood glucose</measure>
    <time_frame>at baseline, 3, and 6 months of follow-up</time_frame>
  </primary_outcome>
  <enrollment type="Actual">240</enrollment>
  <condition>Coronary Artery Disease</condition>
  <condition>Hypertension</condition>
  <condition>Dyslipidemia</condition>
  <condition>Diabetes</condition>
  <intervention>
    <intervention_type>Drug</intervention_type>
    <intervention_name>magnesium L-lactate</intervention_name>
  </intervention>
  <eligibility>
    <criteria>
      <textblock>
        Inclusion Criteria:

          -  Newly implanted ICD or recent ICD shock (within 6 months)

        Exclusion Criteria:

          -  Inability to swallow

          -  A non-cardiac disease with a survival prognosis of less than 12 months

          -  Hypermagnesemia

          -  Creatinine clearance less than 30mL/min

          -  Lactic acidosis or systemic acidosis syndrome

          -  Previous intolerance to magnesium L-lactate
      </textblock>
    </criteria>
    <gender>All</gender>
    <minimum_age>18 Years</minimum_age>
    <maximum_age>N/A</maximum_age>
    <healthy_volunteers>No</healthy_volunteers>
  </eligibility>
  <overall_official>
    <last_name>Charles M White, PharmD</last_name>
    <role>Principal Investigator</role>
    <affiliation>University of Connecticut School of Pharmacy, Hartford Hospital Division of Drug Information</affiliation>
  </overall_official>
  <location>
    <facility>
      <name>Hartford Hospital</name>
      <address>
        <city>Hartford</city>
        <state>Connecticut</state>
        <zip>06102-5037</zip>
        <country>United States</country>
      </address>
    </facility>
  </location>
  <location_countries>
    <country>United States</country>
  </location_countries>
  <verification_date>May 2019</verification_date>
  <study_first_submitted>January 25, 2006</study_first_submitted>
  <study_first_submitted_qc>January 25, 2006</study_first_submitted_qc>
  <study_first_posted type="Estimate">January 27, 2006</study_first_posted>
  <last_update_submitted>May 17, 2019</last_update_submitted>
  <last_update_submitted_qc>May 17, 2019</last_update_submitted_qc>
  <last_update_posted type="Actual">May 21, 2019</last_update_posted>
  <responsible_party>
    <responsible_party_type>Sponsor</responsible_party_type>
  </responsible_party>
  <keyword>Hemodynamics</keyword>
  <keyword>Hypertension</keyword>
  <keyword>Dyslipidemia</keyword>
  <keyword>Diabetes</keyword>
  <keyword>Implantable Cardioverter Defibrillator</keyword>
  <keyword>Blood Pressure</keyword>
  <condition_browse>
    <!-- CAUTION:  The following MeSH terms are assigned with an imperfect algorithm            -->
    <mesh_term>Hypertension</mesh_term>
    <mesh_term>Coronary Artery Disease</mesh_term>
    <mesh_term>Dyslipidemias</mesh_term>
  </condition_browse>
  <!-- Results have not yet been posted for this study                                          -->
</clinical_study>

